Biopharma Launch Stakeholder Engagement Benchmarks

STUDY OVERVIEW
BENCHMARK CLASS
SPECIAL OFFER

Non-members: Click here to review a complimentary excerpt from “Win or Lose at Biopharma Launch: Stakeholder Engagement and Education”

STUDY OVERVIEW

Effective stakeholder engagement begins well before launch and must be tailored to each audience. Physicians, payers, and patients require fundamentally different engagement approaches to translate the same clinical data into adoption, coverage, and adherence. The organizations that consistently outperform build these audience-specific strategies early and concentrate resources on the engagement tactics proven to create impact.

This benchmarking study gives commercial and launch leaders the data needed to assess and strengthen their pre-launch stakeholder engagement strategy. Drawing on insights from 8 launch leaders across 7 leading biopharma companies, the research benchmarks resource allocation across stakeholder groups, positioning effectiveness for physicians, payers, and patients, thought leader engagement tactics, physician and payer education approaches, and patient advocacy strategies. The findings help leaders identify where to concentrate engagement resources and which tactics most reliably drive stakeholder readiness before launch.

Key Questions This Benchmarking Study Answers:

How are peer organizations allocating pre-launch engagement resources across physicians, thought leaders, payers, and patients?
Which positioning dimensions most effectively differentiate products for physicians, payers, and patients?
Which thought leader engagement tactics generate the strongest pre-launch scientific impact?
Which payer education activities are most effective, and where do most organizations fall short?
What patient advocacy and education approaches generate the greatest launch readiness?

KEY TOPICS

Pre-Launch Resource Allocation Across Physician, Thought Leader, Payer, and Patient Stakeholders
Physician Positioning Effectiveness by Dimension and Competitive Context
Payer Positioning and Education Activity Effectiveness
Patient Positioning and Advocacy Program Benchmarks
Thought Leader Engagement Effectiveness by Tactic and Competitive Context
Physician Education Activity Effectiveness and Digital Channel Performance

KEY METRICS

Phase III-to-launch resource allocation benchmarks by stakeholder segment and competitive context
Physician positioning effectiveness ratings across clinical dimensions by competitive archetype
Payer differentiation effectiveness ratings and payer education activity benchmarks
Patient positioning effectiveness ratings by audience dimension
Thought leader engagement tactic effectiveness rankings
Physician education activity effectiveness benchmarks including digital and KOL-based approaches
Patient advocacy and education activity effectiveness benchmarks

SAMPLE KEY FINDINGS

Scientific Engagement Consistently Outperforms Digital Channels: Clinical data sharing and protocol input with thought leaders (75% highly effective) and KOL development with physicians (63%) lead all pre-launch engagement tactics. Digital and social channels consistently underperform, yet digital under-resourcing and promotional complexity are the execution risks most expected to rise over the next 24-36 months -- revealing a critical misalignment between emerging investment trends and proven impact. Physician education (36%) and thought leader engagement (28%) absorb two-thirds of Phase III-to-launch budgets, and the evidence suggests this allocation is well-placed.

METHODOLOGY

Best Practices, LLC benchmarked 8 launch leaders across 7 leading biopharma companies through a quantitative benchmarking survey. The research examines pre-launch stakeholder engagement strategy, resource allocation, and education effectiveness, with findings segmented by competitive context to help leaders benchmark their engagement approach against peer organizations.

Industries Profiled:
Biotech; Manufacturing; Pharmaceutical; Consumer Products

Companies Profiled:
Biogen; L�kahi Therapeutics; LEO Pharma; Novartis; Servier; Vertex; Viking Therapeutics

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Kieu My Tucker at (919) 767-9223 if you have any questions.

Win or Lose at Biopharma Launch: Stakeholder Engagement and Education

ID: 5922

Features:

Pages/Slides: 31

Published: 2026

Delivery Format: Online PDF Document

RELATED RESEARCH

1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60CE39F7CCD0C0F8C00258E6400430BD1
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-stakeholder-engagement-education-biopharma-launch
18
19
20216.73.216.20
21
22
23www.emed24.net
24/bestp/domrep.nsf
25DB